Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymostimulin treatment in AIDS-related complex.

L Palmisano1, T Chisesi, M Galli

  • 1Industria Farmaceutica Serono, Rome, Italy.

Clinical Immunology and Immunopathology
|June 1, 1988
PubMed
Summary

Thymostimulin treatment improved immune function and clinical symptoms in patients with AIDS-related complex (ARC). This thymic hormone therapy showed potential in managing ARC and preventing progression to AIDS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

ESMO open·2024
Same author

Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.

Scientific reports·2021
Same author

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.

Scientific reports·2020
Same author

Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study).

The Journal of antimicrobial chemotherapy·2020
Same author

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

HIV medicine·2020
Same author

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons.

The Journal of frailty & aging·2019

Area of Science:

  • Immunology
  • Virology
  • Clinical Medicine

Background:

  • AIDS-related complex (ARC) is a precursor to Acquired Immunodeficiency Syndrome (AIDS).
  • Current management of ARC often focuses on supportive care and antiviral therapies.
  • Immunological deficiencies are a hallmark of ARC, contributing to disease progression.

Purpose of the Study:

  • To evaluate the efficacy of thymostimulin, a thymic hormone, in managing ARC.
  • To assess the impact of thymostimulin on clinical and immunological parameters in ARC patients.
  • To determine if thymostimulin can prevent the progression of ARC to AIDS.

Main Methods:

  • A 6-month clinical trial involving 34 patients with ARC treated with thymostimulin.
  • Comparison with 24 age- and sex-matched controls receiving no immunotherapy.

Related Experiment Videos

  • Clinical assessments and immunological tests (leukocyte and lymphocyte counts, intradermal antigen tests, T-cell subset analysis) performed at baseline, 6 months, and 12 months.
  • Follow-up for 18 months to monitor disease progression.

    • Main Results:

    • Thymostimulin treatment led to significant improvements in leukocyte and lymphocyte counts.
    • Treated patients showed enhanced immune responses to recall antigens and reduced lymphadenopathy and weight loss.
    • T-cell subsets (OKT3+, OKT4+) remained stable in the thymostimulin group, unlike the control group.
    • No progression to AIDS was observed in the thymostimulin group after 18 months, compared to 3 cases in the control group.

    Conclusions:

    • Thymostimulin demonstrates significant clinical and immunological benefits in ARC patients.
    • The thymic hormone appears to stabilize key immune parameters and prevent disease progression.
    • Thymostimulin may be a valuable therapeutic option for ARC management, potentially combined with antiviral drugs.